Sign In
11 Mar 2011 12:34
Cyprotex PLC ("Cyprotex" or the "Company")
Revised date for Results
Cyprotex PLC (LSE:CRX), the preclinical ADME Tox services company today announces that its final results for the year ended 31 December 2010 will be released on 23 March 2011 rather than 24 March 2011 as announced on 1 March 2011.
Enquiries:
Cyprotex PLC | Tel: +44 (0) 1625 505 100 |
Dr Anthony Baxter, Chief Executive Officer John Dootson, Chief Financial Officer Mark Warburton, Chief Operating Officer and Legal Counsel | |
ir@cyprotex.com | www.cyprotex.com |
Singer Capital Markets Limited (broker to Cyprotex) | Tel: +44 (0) 203 205 7500 |
Shaun Dobson shaun.dobson@singercm.com | |
Claes Spång | |
claes.spang@singercm.com | www.singerscm.com |
Financial Dynamics | Tel: +44 (0) 20 7831 3113 |
Ben Brewerton Ben Atwell Mo Noonan | |
cyprotex@fd.com | www.fd.com |
Notes to Editors:
Cyprotex PLC
Cyprotex is the world's largest contract research organisation (CRO) specialising in ADME Tox, which is the analysis of the Absorption, Distribution, Metabolism, Excretion and Toxicity properties of potential drugs, cosmetics, and agrochemicals. It is the only company in the world with in-house capabilities for both in vitro (test tube) and in silico (computer modelling) ADME Tox. Cyprotex was founded in 1999 and listed on the AIM in 2002. It has laboratories in Macclesfield, Cheshire, UK (near Manchester), and Watertown, Massachusetts, USA (near Boston), making it one of only three ADME Tox CROs with international operations.
www.cyprotex.com
CRX.L (CRX)
Follow the stocks
